SXTP
60 Degrees Pharmaceuticals, Inc. (SXTP) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
SXTP’s environmental risk profile is moderate, with low direct emissions but limited formal sustainability disclosures and controls. The company’s R&D focus reduces its environmental footprint, but the absence of structured environmental programs and recent waste events highlight areas for improvement.
Social
SXTP’s social profile is moderate, driven by its focus on neglected diseases and some community engagement. However, limited workforce and diversity disclosures constrain a higher score, and the company would benefit from greater transparency and formalized social policies.
Governance
SXTP’s governance is moderate, with strengths in scientific leadership and financial discipline but offset by limited board transparency and formal governance disclosures. Enhanced reporting and independent oversight would strengthen its profile.
Overall Score
SXTP’s ESG profile is moderate across all pillars. The company’s R&D focus and commitment to neglected diseases are positives, but limited transparency in environmental, social, and governance disclosures constrain its score. Persistent financial losses and recent operational challenges further temper the assessment. SXTP would benefit from formalizing ESG policies and improving public reporting to align with sector leaders.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on 60 Degrees Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.